Analysts Set Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Price Target at $12.77

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) have earned an average rating of “Buy” from the fifteen analysts that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, twelve have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $12.7692.

Several research analysts have issued reports on TSHA shares. BMO Capital Markets increased their price objective on Taysha Gene Therapies from $10.00 to $14.00 and gave the stock an “outperform” rating in a research note on Tuesday, June 23rd. Robert W. Baird boosted their target price on shares of Taysha Gene Therapies from $12.00 to $15.00 and gave the company an “outperform” rating in a research note on Tuesday, June 30th. The Goldman Sachs Group increased their target price on shares of Taysha Gene Therapies from $11.00 to $13.00 and gave the stock a “buy” rating in a research report on Tuesday, July 21st. Citizens Jmp reissued a “market outperform” rating and set a $11.00 price target on shares of Taysha Gene Therapies in a report on Thursday, July 2nd. Finally, Wolfe Research started coverage on shares of Taysha Gene Therapies in a research report on Thursday. They issued an “outperform” rating on the stock.

Taysha Gene Therapies Stock Down 2.7%

Shares of TSHA opened at $5.02 on Friday. The company has a quick ratio of 17.76, a current ratio of 17.76 and a debt-to-equity ratio of 0.13. The company has a 50-day moving average price of $5.79 and a two-hundred day moving average price of $5.66. The stock has a market cap of $1.64 billion, a price-to-earnings ratio of -11.95 and a beta of 1.19. Taysha Gene Therapies has a 12 month low of $2.71 and a 12 month high of $7.30.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its earnings results on Tuesday, August 11th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). Equities analysts predict that Taysha Gene Therapies will post -0.52 EPS for the current fiscal year.

Insider Activity

In other news, insider Sukumar Nagendran sold 200,000 shares of Taysha Gene Therapies stock in a transaction that occurred on Friday, July 10th. The shares were sold at an average price of $6.24, for a total value of $1,248,000.00. Following the completion of the transaction, the insider owned 936,410 shares in the company, valued at approximately $5,843,198.40. The trade was a 17.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 3.48% of the company’s stock.

Institutional Investors Weigh In On Taysha Gene Therapies

Hedge funds and other institutional investors have recently bought and sold shares of the business. R Squared Ltd bought a new stake in shares of Taysha Gene Therapies during the first quarter worth $50,000. Y Intercept Hong Kong Ltd bought a new position in shares of Taysha Gene Therapies in the first quarter valued at about $51,000. Principal Financial Group Inc. raised its holdings in shares of Taysha Gene Therapies by 26.2% in the first quarter. Principal Financial Group Inc. now owns 16,185 shares of the company’s stock valued at $72,000 after buying an additional 3,362 shares during the last quarter. Legato Capital Management LLC acquired a new position in Taysha Gene Therapies during the 4th quarter worth about $83,000. Finally, Cetera Investment Advisers lifted its position in Taysha Gene Therapies by 34.5% during the 1st quarter. Cetera Investment Advisers now owns 28,450 shares of the company’s stock worth $127,000 after buying an additional 7,296 shares in the last quarter. 77.70% of the stock is owned by institutional investors and hedge funds.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc is a clinical-stage biotechnology company developing gene therapies for severe monogenic diseases of the central nervous system. The company focuses on disorders in which a missing or defective gene contributes to neurological disease and uses adeno-associated virus (AAV) vectors to deliver functional genetic material to targeted cells.

Taysha’s development programs have included TSHA-102, an investigational gene therapy for Rett syndrome, and earlier programs such as TSHA-120 for giant axonal neuropathy and TSHA-101 for GM1 gangliosidosis.